ProstACT GLOBAL is the first Phase III trial to evaluate TLX591 in adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) administered together with Standard of Care (SoC, androgen receptor inhibition or taxanes) versus SoC alone.
ProstACT GLOBAL (ClinicalTrials.gov ID: NCT04876651) is a multinational, multicenter, prospective, randomised, controlled, open-label Phase 3 study to evaluate a new form of radionuclide therapy for patients with metastatic, castrate resistant prostate cancer. APC was the second site activated globally for this phase 3 trial.
This study is examining TLX591, a PSMA-targeting antibody bound to lutetium-177 for metastatic castration-resistant prostate cancer treatment. Unlike other PSMA-targeted therapies requiring multiple cycles, TLX591 involves only two does given two weeks apart.
